Set the goal, describe the patient, and the tool steers toward, cautions, or flags peptides to avoid β with dosing, mechanism, monitoring, and a suggested alternative when something isn't the right fit. Tap any peptide to expand the full detail.
Clinical decision support for licensed clinicians β not a protocol, not a directive. Dosing is reference from the library; verify, individualize, and confirm current sourcing & regulatory status before prescribing. Your clinical judgment governs.
Administration: most peptides here are given subcutaneously (SC) or intramuscularly (IM) β SC is the most common route; the route shown per peptide is the typical reference and SC/IM applies broadly. Current U.S. compounding limits affect sourcing, not the route of administration.
Primary goal
Immune picture
Patient factors (click all that apply)
\u2715
Abbreviations & Glossary
Every abbreviation used in this tool, spelled out.
\u2715
References
Curated key literature behind the entries β the evidence basis, not an exhaustive bibliography. Numbers appear on each peptide card.
β
Malignancy Screening & Lab Monitoring
Consolidated so you don't have to search β the pre-start screening and the labs to follow, for the peptides that need them.
Before starting β pro-angiogenic (BPC-157, TB-500) & GH-axis (sermorelin, CJC-1295/ipamorelin, tesamorelin), plus Dihexa & the incretins:
No active or recent cancer; take a thorough personal AND family cancer history.
Confirm age/sex-appropriate cancer screening is current: colonoscopy, mammography, cervical (Pap/HPV), PSA Β± DRE, skin exam, low-dose chest CT for eligible smokers.
GH secretagogues: check IGF-1 at baseline and keep it in the upper half of the age range β never above ULN. Supraphysiologic IGF-1 is the modifiable risk; there is no peptide-specific tumor marker.
Incretins: personal/family MTC or MEN2 is a contraindication; check calcitonin only if there's a specific thyroid concern (not routine).
GHK-Cu: the exception β favorable cancer-gene signature; still coordinate in active cancer.
Tumor-marker panels (CEA, CA-125, CA 19-9, routine PSA-as-screen) are NOT recommended for general pre-peptide screening β poor specificity/false positives. Screening = history + exam + guideline-based age-appropriate screening.
Lab monitoring at a glance (each card lists specifics):